RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.

KRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRASG12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functions, making it an attractive ca...

Descripción completa

Detalles Bibliográficos
Autores: de-la-Puente-Ovejero, Laura, Fernández-Rodríguez, Ana, Francoz, Sarah, Aizpurua, Gonzalo, Lomba-Riego, Lucía, Drosten, Matthias, Guerra, Carmen, Musteanu, Mónica, Barbacid, Mariano, García-Alonso, Sara
Tipo de recurso: artículo
Fecha de publicación:2026
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:dnet:repisalud__::a3776a84b1e4f18ec66c8018666f660f
Acceso en línea:https://hdl.handle.net/20.500.12105/27498
Access Level:acceso abierto
Palabra clave:K-RAS ONCOGENE
A-RAF
B-RAF
PROTEIN-KINASE
APOPTOSIS
MICE
REGRESSION
MUTATIONS
LETHALITY
id ES_663a3eeae3887cfefce05c0eb02ca642
oai_identifier_str oai:dnet:repisalud__::a3776a84b1e4f18ec66c8018666f660f
network_acronym_str ES
network_name_str España
repository_id_str
spelling RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.de-la-Puente-Ovejero, LauraFernández-Rodríguez, AnaFrancoz, SarahAizpurua, GonzaloLomba-Riego, LucíaDrosten, MatthiasGuerra, CarmenMusteanu, MónicaBarbacid, MarianoGarcía-Alonso, SaraK-RAS ONCOGENEA-RAFB-RAFPROTEIN-KINASEAPOPTOSISMICEREGRESSIONMUTATIONSLETHALITYKRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRASG12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functions, making it an attractive candidate for targeted protein degradation. However, the therapeutic impact and safety of co-targeting RAF1 with related kinases remain unclear.PUBLIC LIBRARY SCIENCEmadridComunidad de Madrid (España)Ministerio de Ciencia e Innovación (España)Fundación La CaixaCentro de Investigación Biomédica en Red - CIBERONC (Cáncer)Agencia Estatal de Investigación (España)20262026-06-0220262026-01-0120262026-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.12105/27498reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)InglésengAgencia Estatal de Investigación http://dx.doi.org/10.13039/501100011033 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTI2018-094664-B-I00 C-RAF, UN MEDIADOR CLAVE EN TUMORES INDUCIDOS POR EL ONCOGEN K-RAS: ESTRATEGIAS TERAPEUTICASopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:dnet:repisalud__::a3776a84b1e4f18ec66c8018666f660f2026-06-12T12:43:37Z
dc.title.none.fl_str_mv RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
title RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
spellingShingle RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
de-la-Puente-Ovejero, Laura
K-RAS ONCOGENE
A-RAF
B-RAF
PROTEIN-KINASE
APOPTOSIS
MICE
REGRESSION
MUTATIONS
LETHALITY
title_short RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
title_full RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
title_fullStr RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
title_full_unstemmed RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
title_sort RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.
dc.creator.none.fl_str_mv de-la-Puente-Ovejero, Laura
Fernández-Rodríguez, Ana
Francoz, Sarah
Aizpurua, Gonzalo
Lomba-Riego, Lucía
Drosten, Matthias
Guerra, Carmen
Musteanu, Mónica
Barbacid, Mariano
García-Alonso, Sara
author de-la-Puente-Ovejero, Laura
author_facet de-la-Puente-Ovejero, Laura
Fernández-Rodríguez, Ana
Francoz, Sarah
Aizpurua, Gonzalo
Lomba-Riego, Lucía
Drosten, Matthias
Guerra, Carmen
Musteanu, Mónica
Barbacid, Mariano
García-Alonso, Sara
author_role author
author2 Fernández-Rodríguez, Ana
Francoz, Sarah
Aizpurua, Gonzalo
Lomba-Riego, Lucía
Drosten, Matthias
Guerra, Carmen
Musteanu, Mónica
Barbacid, Mariano
García-Alonso, Sara
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv madrid
Comunidad de Madrid (España)
Ministerio de Ciencia e Innovación (España)
Fundación La Caixa
Centro de Investigación Biomédica en Red - CIBERONC (Cáncer)
Agencia Estatal de Investigación (España)
dc.subject.none.fl_str_mv K-RAS ONCOGENE
A-RAF
B-RAF
PROTEIN-KINASE
APOPTOSIS
MICE
REGRESSION
MUTATIONS
LETHALITY
topic K-RAS ONCOGENE
A-RAF
B-RAF
PROTEIN-KINASE
APOPTOSIS
MICE
REGRESSION
MUTATIONS
LETHALITY
description KRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRASG12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functions, making it an attractive candidate for targeted protein degradation. However, the therapeutic impact and safety of co-targeting RAF1 with related kinases remain unclear.
publishDate 2026
dc.date.none.fl_str_mv 2026
2026-06-02
2026
2026-01-01
2026
2026-01-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/27498
url https://hdl.handle.net/20.500.12105/27498
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.relation.none.fl_str_mv Agencia Estatal de Investigación http://dx.doi.org/10.13039/501100011033 Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 RTI2018-094664-B-I00 C-RAF, UN MEDIADOR CLAVE EN TUMORES INDUCIDOS POR EL ONCOGEN K-RAS: ESTRATEGIAS TERAPEUTICAS
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv PUBLIC LIBRARY SCIENCE
publisher.none.fl_str_mv PUBLIC LIBRARY SCIENCE
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409800618508288
score 15,81155

Similares en LA Referencia